Theravance Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-11.8%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
$0.21next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
YUPELRI Collaboration Revenue Quarterly17.7M
Quarter-end Cash Balance Quarterly394.7M
YUPELRI Implied 35% Share of Net Sales Quarterly21.9M
Watch Items
- TRELEGY 2026 Net Sales Milestone PaymentTrigger: GSK-reported global TRELEGY net sales exceeding $3.51 billionAction: Collect $100.0 million milestone payment from Royalty Pharma
- Organizational Restructuring Cost SavingsTrigger: 60% reduction in operating expenses relative to 2025 actuals ($111.1 million)Action: Verify full run-rate savings of ~$70.0 million starting in Q3 2026
- Strategic Review Committee OutcomesTrigger: Board evaluation of strategic alternatives and potential sale of YUPELRI royalty streamAction: Monitor corporate announcements regarding strategic transactions or capital returns
Research as of 19 Jun 2026